XTLB vs. CARM, CALC, RPHM, RMTI, ANEB, BLRX, KZR, EQ, EGRX, and CASI
Should you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include Carisma Therapeutics (CARM), CalciMedica (CALC), Reneo Pharmaceuticals (RPHM), Rockwell Medical (RMTI), Anebulo Pharmaceuticals (ANEB), BioLineRx (BLRX), Kezar Life Sciences (KZR), Equillium (EQ), Eagle Pharmaceuticals (EGRX), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical preparations" industry.
Carisma Therapeutics (NASDAQ:CARM) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking.
XTL Biopharmaceuticals has a net margin of 0.00% compared to XTL Biopharmaceuticals' net margin of -538.81%. Carisma Therapeutics' return on equity of -73.05% beat XTL Biopharmaceuticals' return on equity.
XTL Biopharmaceuticals received 67 more outperform votes than Carisma Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Carisma Therapeutics an outperform vote while only 71.82% of users gave XTL Biopharmaceuticals an outperform vote.
XTL Biopharmaceuticals has lower revenue, but higher earnings than Carisma Therapeutics.
44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 17.0% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Carisma Therapeutics had 3 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 4 mentions for Carisma Therapeutics and 1 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 1.59 beat Carisma Therapeutics' score of 0.00 indicating that Carisma Therapeutics is being referred to more favorably in the media.
Carisma Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, XTL Biopharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
Carisma Therapeutics presently has a consensus target price of $9.00, indicating a potential upside of 587.02%. Given XTL Biopharmaceuticals' higher probable upside, equities analysts clearly believe Carisma Therapeutics is more favorable than XTL Biopharmaceuticals.
Summary
Carisma Therapeutics and XTL Biopharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.
Get XTL Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
XTL Biopharmaceuticals Competitors List
Related Companies and Tools
